# Jiangsu Hansoh Pharmaceutical Co., Ltd. trials: 138 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 138 trials with Jiangsu Hansoh Pharmaceutical Co., Ltd. as lead sponsor, 52 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Jiangsu Hansoh Pharmaceutical Co., Ltd.: 138 rows for $6.90, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 4 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/jiangsu-hansoh-pharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 138
- Recruiting or not yet: 52
- Read on: November 19, 2026

## Trials

The 25 newest of 138, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07933224 | A Phase I Study to Evaluate the Effect of Food on the Pharmacokinetics of HS-10382 Tablets in Healthy Participants | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Healthy Volunteers | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933224) |
| November 3, 2026 | NCT07911787 | Phase 3 Study of HS-10380 for Acute Schizophrenia in Chinese Adults | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | SCHIZOPHRENIA 1 (Disorder) | 476 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911787) |
| October 27, 2026 | NCT07896915 | A Study to Evaluate the Pharmacokinetic Characteristics of HS-20118 Under Different Dosing Conditions in Healthy Participants | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 | Active not recruiting | Healthy Participants | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896915) |
| October 21, 2026 | NCT07885293 | A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Chronic Myeloid Leukemia | 408 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07885293) |
| September 28, 2026 | NCT07844967 | A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of HS-10506 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Hepatic Impairment (Moderate or Mild) & Normal Hepatic Function | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07844967) |
| September 23, 2026 | NCT07836504 | A Pharmacokinetic Study of HS-10504 in Participants With Hepatic Impairment and Normal Hepatic Function. | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | To Compare the Pharmacokinetic (PK) Differences of HS-10504 Between Participants With Hepatic Impairment and... | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07836504) |
| September 16, 2026 | NCT07822542 | A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as... | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Carcinoma, Non-Small-Cell Lung | 448 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07822542) |
| August 20, 2026 | NCT07777003 | A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10582 in Healthy Subjects and Subjects With Mildly... | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Dyslipidemia | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07777003) |
| August 18, 2026 | NCT07770217 | A Phase I Clinical Trial to Evaluate Pharmacokinetics of HS-10504 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Healthy Participants | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07770217) |
| August 14, 2026 | NCT07765628 | A Phase 2 Study of HS-20118 to Evaluate the Efficacy and Safety in Participant With Moderate-to-Severe Plaque Psoriasis | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Moderate to Severe Plaque Psoriasis | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07765628) |
| August 14, 2026 | NCT07764705 | A Mass Balance Study of \[14C\]HS-10504 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Healthy Subjects | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07764705) |
| August 14, 2026 | NCT07764692 | A Phase I Clinical Trial to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HS-10504 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Healthy Participants | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07764692) |
| August 12, 2026 | NCT07759869 | A Study to Evaluate the Long-term Safety of HS-10380 in Patients With Schizophrenia | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | SCHIZOPHRENIA 1 (Disorder) | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07759869) |
| August 10, 2026 | NCT07754123 | Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Advanced or Metastatic NSCLC | 206 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07754123) |
| July 21, 2026 | NCT07716241 | A Phase I Study of Single and Multiple Doses of HS-20136-2 Injection in Healthy or Obese Participants | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Obesity | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07716241) |
| July 6, 2026 | NCT07685041 | An Open-label, Fixed-sequence Phase I Clinical Trial to Evaluate the Effect of HS-10504 on the Pharmacokinetics of Midazolam in Patients... | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | NSCLC | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07685041) |
| June 30, 2026 | NCT07677384 | A Study to Evaluate the Safety of HS-10506 in Chinese Patients With Insomnia Disorder | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Insomnia Disorder | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07677384) |
| May 29, 2026 | NCT07615413 | Phase 1 Study of HS-10541 as Monotherapy or in Combination With Other Anti-cancer Therapies in Patients With KRAS G12C Mutation Advanced... | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | KRAS G12C Mutation Advanced Solid Tumor | 636 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07615413) |
| May 27, 2026 | NCT07609875 | A Phase I Single and Multiple Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of HS-10522 in Healthy Chinese... | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Healthy Adult, Hypertension | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07609875) |
| May 14, 2026 | NCT07587385 | A Study of HS-10506 in Chinese Patients With Insomnia Disorder | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Insomnia Disorder | 732 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07587385) |
| May 5, 2026 | NCT07567859 | A Study of HS-10587 in Patients With Advanced Solid Tumors | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | MTAP Deletion | 362 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07567859) |
| April 28, 2026 | NCT07555054 | A Study of the Effect and Safety of HS-10390 in the Treatment of Participants With Chronic Kidney Disease | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Chronic Kidney Disease | 182 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07555054) |
| April 24, 2026 | NCT07550387 | A Study Assessing the Efficacy and Safety of HS-10380 in Hospitalized Adults With Acute Schizophrenia | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 2 | Completed | SCHIZOPHRENIA 1 (Disorder) | 363 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07550387) |
| April 17, 2026 | NCT07535970 | A Phase I Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HS-10506 in Healthy Chinese Adult Participants | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Healthy Participants | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07535970) |
| March 31, 2026 | NCT07503015 | Phase 1 Study of HS-20152 in Healthy Participants | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Healthy Volunteers | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07503015) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 77 |
| Phase 1/2 | 12 |
| Phase 2 | 18 |
| Phase 2/3 | 1 |
| Phase 3 | 25 |
| Phase 4 | 5 |

## By status

| Status | Trials |
| --- | --- |
| Unknown | 58 |
| Not yet recruiting | 35 |
| Completed | 24 |
| Recruiting | 17 |
| Active not recruiting | 4 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 19 |
| Diabetes Mellitus, Type 2 | 12 |
| Schizophrenia | 7 |
| Anemia | 4 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 |
| Obesity | 4 |
| Breast Neoplasms | 4 |
| Leukemia, Myeloid, Chronic-Phase | 4 |
| Hepatitis B, Chronic | 3 |
| Renal Insufficiency, Chronic | 3 |
| Overweight | 3 |
| Psoriasis | 3 |
| Cough | 3 |
| Kidney Failure, Chronic | 3 |
| Sleep Initiation and Maintenance Disorders | 3 |
| Depressive Disorder, Major | 3 |
| Endometriosis | 2 |
| Dyslipidemias | 2 |
| Colorectal Neoplasms | 2 |
| Ovarian Neoplasms | 2 |
| Prostatic Neoplasms | 2 |
| Leukemia, Myeloid, Accelerated Phase | 2 |
| Carcinoma | 1 |
| Cardiomyopathy, Hypertrophic | 1 |
| Cardiomyopathies | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Farm equipment suppliers in the United States](https://specstream.ai/data/businesses/farm-equipment-suppliers/united-states)
- [Well drilling companies in the United States](https://specstream.ai/data/businesses/well-drilling-companies/united-states)
- [Mechanical engineering firms in the United States](https://specstream.ai/data/businesses/mechanical-engineering-firms/united-states)
- [Chimney sweeps in the United States](https://specstream.ai/data/businesses/chimney-sweeps/united-states)
- [Security companies in the United States](https://specstream.ai/data/businesses/security-companies/united-states)
